PMID- 35444114
OWN - NLM
STAT- MEDLINE
DCOM- 20220520
LR  - 20220531
IS  - 1881-7823 (Electronic)
IS  - 1881-7815 (Linking)
VI  - 16
IP  - 2
DP  - 2022 May 17
TI  - Time to onset of drug-induced parkinsonism: Analysis using a large Japanese 
      adverse event self-reporting database.
PG  - 151-157
LID - 10.5582/bst.2022.01115 [doi]
AB  - Whether there are differences in the time to onset of drug-induced parkinsonism 
      (DIP) depending on the type of drugs causing DIP remains uncertain, so that 
      question was investigated here using a large real-world database. Fourteen 
      DIP-related drug categories were defined to perform a disproportionality analysis 
      using a large Japanese pharmacovigilance database containing more than 600,000 
      self-reported adverse events (AEs) recorded between April 2004 and September 2021 
      to identify AEs indicating "parkinsonism" in association with the defined drug 
      categories. The time from drug administration to the onset of DIP was 
      comparatively analyzed. Results indicated that the median time to onset was 
      shorter than 1 month in more than half of the cases of DIP; it was shortest with 
      peripheral dopamine antagonists (median: 0.1 weeks), followed by benzodiazepine 
      (median: 0.5 weeks), butyrophenone (median: 0.7 weeks), novel antidepressants 
      (median: 2.5 weeks), atypical antipsychotics (median: 3.3 weeks), other 
      antidepressants (e.g., lithium, median: 3.7 weeks), and benzamide (median: 4.5 
      weeks). In contrast, anti-dementia drugs, tricyclic antidepressants, and 
      antiepileptic drugs resulted in a relatively longer time to onset (median: 9.9, 
      17.2, and 28.4 weeks, respectively). In addition, a maximum delay of even longer 
      than 2 years was reported for benzamide (846 weeks), anti-Parkinsonism drugs (382 
      weeks), phenothiazine (232 weeks), atypical antipsychotics (167 weeks), 
      anti-dementia drugs (161 weeks), and benzodiazepines (120 weeks). The current 
      results suggested that the characteristics of the time to onset of DIP may 
      substantially differ depending on the type of drug causing that DIP. This finding 
      may help when diagnosing patients with parkinsonism.
FAU - Sato, Kenichiro
AU  - Sato K
AD  - Department of Neuropathology, Graduate School of Medicine, The University of 
      Tokyo, Tokyo, Japan.
AD  - Unit for Early and Exploratory Clinical Development, The University of Tokyo 
      Hospital, Tokyo, Japan.
FAU - Niimi, Yoshiki
AU  - Niimi Y
AD  - Unit for Early and Exploratory Clinical Development, The University of Tokyo 
      Hospital, Tokyo, Japan.
FAU - Mano, Tatsuo
AU  - Mano T
AD  - Department of Neurology, Graduate School of Medicine, The University of Tokyo, 
      Tokyo, Japan.
FAU - Iwata, Atsushi
AU  - Iwata A
AD  - Department of Neurology, Tokyo Metropolitan Geriatric Center Hospital, Tokyo, 
      Japan.
FAU - Iwatsubo, Takeshi
AU  - Iwatsubo T
AD  - Department of Neuropathology, Graduate School of Medicine, The University of 
      Tokyo, Tokyo, Japan.
AD  - Unit for Early and Exploratory Clinical Development, The University of Tokyo 
      Hospital, Tokyo, Japan.
LA  - eng
PT  - Journal Article
DEP - 20220420
PL  - Japan
TA  - Biosci Trends
JT  - Bioscience trends
JID - 101502754
RN  - 0 (Antipsychotic Agents)
RN  - 0 (Benzamides)
SB  - IM
MH  - *Antipsychotic Agents/adverse effects
MH  - Benzamides/adverse effects
MH  - Databases, Factual
MH  - Humans
MH  - Japan/epidemiology
MH  - *Parkinsonian Disorders/chemically induced
MH  - Pharmacovigilance
MH  - Time Factors
OTO - NOTNLM
OT  - adverse events
OT  - drug-induced parkinsonism
OT  - pharmacovigilance
OT  - real-world data
EDAT- 2022/04/22 06:00
MHDA- 2022/05/21 06:00
CRDT- 2022/04/21 05:22
PHST- 2022/04/22 06:00 [pubmed]
PHST- 2022/05/21 06:00 [medline]
PHST- 2022/04/21 05:22 [entrez]
AID - 10.5582/bst.2022.01115 [doi]
PST - ppublish
SO  - Biosci Trends. 2022 May 17;16(2):151-157. doi: 10.5582/bst.2022.01115. Epub 2022 
      Apr 20.